PCM
JANX icon

Prelude Capital Management’s Janux Therapeutics JANX Stock Holding History

Prelude Capital Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$212K Sell
13,800
-2,834
-17% -$41.1K 0.02% 957
2026
Q1 		$231K Sell
16,634
-2,700
-14% -$37K 0.02% 841
2025
Q4 		$267K Buy
+19,334
New +$455K 0.02% 857
2025
Q1 		– Sell
-10,231
Closed -$548K – 1370
2024
Q4 		$548K Buy
+10,231
New +$541K 0.03% 565

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Prelude Capital Management's JANX Position: Q2 2026 in Review

Prelude Capital Management reduced its Janux Therapeutics (JANX) stake by 17% in Q2 2026, selling an estimated $41.1K and leaving 13,800 shares worth $212K. The position accounts for 0.02% of the portfolio, ranked #957.

Prelude Capital Management first reported a position in JANX in Q4 2024 and has held it in 4 quarters since. The position peaked at $548K in Q4 2024. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Prelude Capital Management held 13,800 shares of Janux Therapeutics worth $212K as of Q2 2026.
  • Prelude Capital Management sold 2,834 Janux Therapeutics shares in Q2 2026, an estimated $41.1K.
  • Janux Therapeutics made up 0.02% of Prelude Capital Management's portfolio in Q2 2026, its #957 holding.
  • Prelude Capital Management first reported a position in Janux Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Prelude Capital Management's Janux Therapeutics position peaked at $548K in Q4 2024.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.